title: Strategy to tether organometallic ruthenium-arene anticancer compounds to recombinant human serum albumin.
abstract: In order to utilize macromolecules for drug targeting and delivery, a strategy to tether organometallic ruthenium-arene drugs to carrier protein molecules was developed. The approach involves the design of a drug fragment capable of conjugating to linker molecules on a modified carrier protein via hydrazone bond formation. The proof-of-concept using recombinant human serum albumin is described.
authors.affiliation: Institut des Sciences et Ingénierie Chimiques, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
authors.forename: Wee Han
authors.initials: WH
authors.lastname: Ang
authors.forename: Elisa
authors.initials: E
authors.lastname: Daldini
authors.forename: Lucienne
authors.initials: L
authors.lastname: Juillerat-Jeanneret
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Dyson
mesh_terms: D000970:Antineoplastic Agents / Q000737:chemistry*; D006801:Humans; D009942:Organometallic Compounds / Q000737:chemistry*; D011994:Recombinant Proteins / Q000737:chemistry; D012428:Ruthenium / Q000737:chemistry*; D012709:Serum Albumin / Q000737:chemistry*
chemical_list: D000970:Antineoplastic Agents; D009942:Organometallic Compounds; D011994:Recombinant Proteins; D012709:Serum Albumin; D012428:Ruthenium